Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. März 2025 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).
28. Februar 2025 09:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.
24. September 2024 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the FDA has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for scalp and body psoriasis.
23. Juli 2024 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the submission of an sNDA in scalp and body psoriasis.
13. Oktober 2023 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.